395 related articles for article (PubMed ID: 28780375)
21. A virus-like particle-based tetravalent vaccine for hand, foot, and mouth disease elicits broad and balanced protective immunity.
Zhang W; Dai W; Zhang C; Zhou Y; Xiong P; Wang S; Ye X; Liu Q; Zhou D; Huang Z
Emerg Microbes Infect; 2018 May; 7(1):94. PubMed ID: 29777102
[TBL] [Abstract][Full Text] [Related]
22. Potentiating the Immune Responses of HBsAg-VLP Vaccine Using a Polyphosphoester-Based Cationic Polymer Adjuvant.
Liu X; Liu Y; Yang X; Lu X; Xu XN; Zhang J; Chen R
ACS Appl Mater Interfaces; 2023 Oct; 15(42):48871-48881. PubMed ID: 37816068
[TBL] [Abstract][Full Text] [Related]
23. ISCOMATRIX™ adjuvant promotes epitope spreading and antibody affinity maturation of influenza A H7N9 virus like particle vaccine that correlate with virus neutralization in humans.
Chung KY; Coyle EM; Jani D; King LR; Bhardwaj R; Fries L; Smith G; Glenn G; Golding H; Khurana S
Vaccine; 2015 Jul; 33(32):3953-62. PubMed ID: 26093202
[TBL] [Abstract][Full Text] [Related]
24. Influenza virosomes as vaccine adjuvant and carrier system.
Moser C; Müller M; Kaeser MD; Weydemann U; Amacker M
Expert Rev Vaccines; 2013 Jul; 12(7):779-91. PubMed ID: 23885823
[TBL] [Abstract][Full Text] [Related]
25. Enterovirus type 71 neutralizing antibodies in the serum of macaque monkeys immunized with EV71 virus-like particles.
Lin YL; Yu CI; Hu YC; Tsai TJ; Kuo YC; Chi WK; Lin AN; Chiang BL
Vaccine; 2012 Feb; 30(7):1305-12. PubMed ID: 22214888
[TBL] [Abstract][Full Text] [Related]
26. Delivering adjuvants and antigens in separate nanoparticles eliminates the need of physical linkage for effective vaccination.
Mohsen MO; Gomes AC; Cabral-Miranda G; Krueger CC; Leoratti FM; Stein JV; Bachmann MF
J Control Release; 2017 Apr; 251():92-100. PubMed ID: 28257987
[TBL] [Abstract][Full Text] [Related]
27. Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine: results from a double-blinded, randomized Phase I clinical trial in healthy Asian volunteers.
Low JG; Lee LS; Ooi EE; Ethirajulu K; Yeo P; Matter A; Connolly JE; Skibinski DA; Saudan P; Bachmann M; Hanson BJ; Lu Q; Maurer-Stroh S; Lim S; Novotny-Diermayr V
Vaccine; 2014 Sep; 32(39):5041-8. PubMed ID: 25045806
[TBL] [Abstract][Full Text] [Related]
28. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL
J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749
[TBL] [Abstract][Full Text] [Related]
29. Progress in developing virus-like particle influenza vaccines.
Quan FS; Lee YT; Kim KH; Kim MC; Kang SM
Expert Rev Vaccines; 2016 Oct; 15(10):1281-93. PubMed ID: 27058302
[TBL] [Abstract][Full Text] [Related]
30. Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus.
Fotouhi F; Shaffifar M; Farahmand B; Shirian S; Saeidi M; Tabarraei A; Gorji A; Ghaemi A
Arch Virol; 2017 May; 162(5):1251-1260. PubMed ID: 28120096
[TBL] [Abstract][Full Text] [Related]
31. Bacterial superglue enables easy development of efficient virus-like particle based vaccines.
Thrane S; Janitzek CM; Matondo S; Resende M; Gustavsson T; de Jongh WA; Clemmensen S; Roeffen W; van de Vegte-Bolmer M; van Gemert GJ; Sauerwein R; Schiller JT; Nielsen MA; Theander TG; Salanti A; Sander AF
J Nanobiotechnology; 2016 Apr; 14():30. PubMed ID: 27117585
[TBL] [Abstract][Full Text] [Related]
32. Novel Respiratory Syncytial Virus-Like Particle Vaccine Composed of the Postfusion and Prefusion Conformations of the F Glycoprotein.
Cimica V; Boigard H; Bhatia B; Fallon JT; Alimova A; Gottlieb P; Galarza JM
Clin Vaccine Immunol; 2016 Jun; 23(6):451-9. PubMed ID: 27030590
[TBL] [Abstract][Full Text] [Related]
33. Engineering virus-like particles as vaccine platforms.
Frietze KM; Peabody DS; Chackerian B
Curr Opin Virol; 2016 Jun; 18():44-9. PubMed ID: 27039982
[TBL] [Abstract][Full Text] [Related]
34. A Single Intramuscular Dose of a Plant-Made Virus-Like Particle Vaccine Elicits a Balanced Humoral and Cellular Response and Protects Young and Aged Mice from Influenza H1N1 Virus Challenge despite a Modest/Absent Humoral Response.
Hodgins B; Yam KK; Winter K; Pillet S; Landry N; Ward BJ
Clin Vaccine Immunol; 2017 Dec; 24(12):. PubMed ID: 29021303
[TBL] [Abstract][Full Text] [Related]
35. Virus-like particles: potential veterinary vaccine immunogens.
Liu F; Ge S; Li L; Wu X; Liu Z; Wang Z
Res Vet Sci; 2012 Oct; 93(2):553-9. PubMed ID: 22100244
[TBL] [Abstract][Full Text] [Related]
36. Virus-Like Particle (VLP) Plus Microcrystalline Tyrosine (MCT) Adjuvants Enhance Vaccine Efficacy Improving T and B Cell Immunogenicity and Protection against Plasmodium berghei/vivax.
Cabral-Miranda G; Heath MD; Mohsen MO; Gomes AC; Engeroff P; Flaxman A; Leoratti FMS; El-Turabi A; Reyes-Sandoval A; Skinner MA; Kramer MF; Bachmann MF
Vaccines (Basel); 2017 May; 5(2):. PubMed ID: 28468322
[TBL] [Abstract][Full Text] [Related]
37. Tetravalent recombinant dengue virus-like particles as potential vaccine candidates: immunological properties.
Liu Y; Zhou J; Yu Z; Fang D; Fu C; Zhu X; He Z; Yan H; Jiang L
BMC Microbiol; 2014 Dec; 14():233. PubMed ID: 25520151
[TBL] [Abstract][Full Text] [Related]
38. A virus-like particle vaccine candidate for influenza A virus based on multiple conserved antigens presented on hepatitis B tandem core particles.
Ramirez A; Morris S; Maucourant S; D'Ascanio I; Crescente V; Lu IN; Farinelle S; Muller CP; Whelan M; Rosenberg W
Vaccine; 2018 Feb; 36(6):873-880. PubMed ID: 29306508
[TBL] [Abstract][Full Text] [Related]
39. Real-time stability of a hepatitis E vaccine (Hecolin®) demonstrated with potency assays and multifaceted physicochemical methods.
Zhang X; Wei M; Sun G; Wang X; Li M; Lin Z; Li Z; Li Y; Fang M; Zhang J; Li S; Xia N; Zhao Q
Vaccine; 2016 Nov; 34(48):5871-5877. PubMed ID: 27793484
[TBL] [Abstract][Full Text] [Related]
40. A virus-like particle vaccination strategy expands its tolerance to H3N2 antigenic drift by enhancing neutralizing antibodies against hemagglutinin stalk.
Yang JR; Cheng CY; Chen CY; Lin CH; Kuo CY; Huang HY; Wu FT; Yang YC; Wu CY; Liu MT; Hsiao PW
Antiviral Res; 2017 Apr; 140():62-75. PubMed ID: 28093338
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
